Are you Dr. Das?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 45 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3030 Bunker Hill St
Suite # 230
San Diego, CA 92109Phone+1 858-336-0468- Is this information wrong?
Summary
- Dr. Asha Das, MD is a board certified neurologist in San Diego, California. She is currently licensed to practice medicine in California, Virginia, and Massachusetts.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1991 - 1994
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1991
- Weill Cornell MedicineClass of 1989
Certifications & Licensure
- CA State Medical License 2001 - 2024
- VA State Medical License 2022 - 2024
- MA State Medical License 1994 - 2012
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 19 citationsMolecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in PatientsDaniel J. Hogan, Jay-Jiguang Zhu, Oscar Diago, Dawn Gammon, Ali Haghighi, Guangrong Lu, Asha Das, Harry E. Gruber, Douglas J. Jolly, Derek Ostertag> ;Clinical Cancer Research. 2018 Oct 1
- 116 citationsDurable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.Timothy F. Cloughesy, Joseph Landolfi, Michael A. Vogelbaum, Derek Ostertag, James B. Elder, Stephen Bloomfield, Bob S. Carter, Clark C. Chen, Steven N. Kalkanis, Sant...> ;Neuro-Oncology. 2018 Sep 3
- 5 citationsModeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.Kelong Han, Laurent Claret, Alan Sandler, Asha Das, Jin Jin, Rene Bruno> ;BMC Cancer. 2016 Jul 13
- Join now to see all
Press Mentions
- PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial ShowsJuly 25th, 2019
- Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate CancerJune 25th, 2019
- Progenics: Placing Catalysts into ContextMay 7th, 2019
- Join now to see all
Professional Memberships
- Member